Search

This letter to the editor discusses a rare case of acute macular neuroretinopathy (AMN) as an atypical immune effector cell-associated neurotoxicity syndrome (ICANS) manifestation following CAR-T cell infusion. The patient, a 64-year-old woman with refractory mantle cell lymphoma, developed ocular symptoms after CAR-T cell therapy, including vision loss and floaters. Treatment with anakinra and dexamethasone led to symptom improvement, suggesting a potential lifelong adverse event related to CAR-T infusion. Ophthalmologists should be involved in cases of ocular symptoms post-CAR-T infusion, especially when accompanied by classical ICANS manifestations. [Extracted from the article]

The success of a classic inorganic coordination compound, Cisplatin, cis-[Pt(NH 3 ) 2 Cl 2 ], as the first anticancer metallodrug started a field of research dedicated to discovering coordination compounds with antitumor activity, encompassing various metals. Among these, copper complexes have emerged as interesting candidates to develop drugs to treat cancer. In this work, mixed ligand complexes of Cu(II) with diimines (phenanthroline or 4-methylphenanthroline) and 3-(4-hydroxyphenyl)propanoate, phenylcarboxylate or phenylacetate were synthesized. They were characterized in the solid state, including a new crystal structure of [Cu 2 (3-(4-hydroxyphenyl)propanoate) 3 (phenanthroline) 2 ]Cl·H 2 O. The obtained complexes presented a variety of stoichiometries. In solution, complexes were partially dissociated in the corresponding Cu-diimine complex. The complexes bound to the DNA by partial intercalation and groove binding, as assessed by Circular Dichroism, relative viscosity change and UV-Vis titration. The cytotoxicity of the complexes was determined in vitro on MDA-MB-231, MCF-7 (human metastatic breast adenocarcinomas, the first triple negative), MCF-10A (breast nontumoral), A549 (human lung epithelial carcinoma), and MRC-5 (human nontumoral lung epithelial cells), finding an activity higher than that of Cisplatin, although with less selectivity., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)